Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

OTC Switch Interest Cooled By Study Costs To Update Safety Data

05 Jul 2017

• By Eileen Francis

Binocular viewer_1200X675

Related Content

Room For Innovative Switches Could Lurk In Existing FDA Framework

29 Oct 2014

Petition Seeks OTC PPI Warning On Cancer Risk From Persistent Heartburn

02 May 2017

FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap

16 May 2017

Naloxone Talk Sheds Light On Switch Research Future

07 Jan 2013

Merck Silence On OTC <em>Singulair</em> Speaks Volumes On Switch Outlook

10 Dec 2015

Light Still On For Switches After Pfizer Pulls Plug On OTC <em>Lipitor</em>

03 Aug 2015

Pharma Firm ISO OTC Switch Partner; NDA Experience, Resources Needed

24 Oct 2016

Differin Gel Enters Changed Marketplace Since Last OTC Acne Drug Approval

22 Aug 2016

Related Companies

Merck & Co., Inc.

GSK plc

Sanofi

Additional Topics

United States Prescription To OTC Switch Drug Approval Standards Advertising, Marketing & Sales Manufacturing OTC Drugs Consumer

More from Approval Standards

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.